MA34655B1 - Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse - Google Patents

Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse

Info

Publication number
MA34655B1
MA34655B1 MA35889A MA35889A MA34655B1 MA 34655 B1 MA34655 B1 MA 34655B1 MA 35889 A MA35889 A MA 35889A MA 35889 A MA35889 A MA 35889A MA 34655 B1 MA34655 B1 MA 34655B1
Authority
MA
Morocco
Prior art keywords
treatment
quinazolein
dihydroimidazo
aminoalcool
substituted
Prior art date
Application number
MA35889A
Other languages
English (en)
Inventor
William Scott
Ningshu Liu
Manfred Moewes
Andrea Haegebarth
Ursula Moenning
Ulf Boemer
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44999756&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34655(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA34655B1 publication Critical patent/MA34655B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CETTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS DE 2,3-DIHYDROIMIDAZO[1,2-C]-QUINAZOLÉINE, LES COMPOSITIONS PHARMACEUTIQUES CONTENANT CES COMPOSÉS ET L'UTILISATION DE CES COMPOSÉS OU COMPOSITIONS POUR L'INHIBITION DE LA PHOSPHOTIDYLINOSITOL-3-KINASE (PI3K) ET LE TRAITEMENT DE MALADIES ASSOCIÉES À L'ACTIVITÉ DE LA PHOSPHOTIDYLINOSITOL-3-KINASE (PI3K), EN PARTICULIER LE TRAITEMENT DES TROUBLES HYPERPROLIFÉRATIFS ET/OU DE L'ANGIOGENÈSE, COMME SEUL AGENT OU EN COMBINAISON AVEC D'AUTRES INGRÉDIENTS ACTIFS.
MA35889A 2010-11-11 2011-11-08 Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse MA34655B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41255610P 2010-11-11 2010-11-11
PCT/EP2011/069637 WO2012062748A1 (fr) 2010-11-11 2011-11-08 Dérivés de 2,3-dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse

Publications (1)

Publication Number Publication Date
MA34655B1 true MA34655B1 (fr) 2013-11-02

Family

ID=44999756

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35889A MA34655B1 (fr) 2010-11-11 2011-11-08 Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse

Country Status (31)

Country Link
US (2) US8895549B2 (fr)
EP (1) EP2638045B1 (fr)
JP (1) JP6196156B2 (fr)
KR (1) KR20140003436A (fr)
CN (1) CN102906094B (fr)
AP (1) AP3337A (fr)
AR (1) AR083842A1 (fr)
AU (1) AU2011328192B2 (fr)
BR (1) BR112013011634A2 (fr)
CA (1) CA2817317C (fr)
CL (1) CL2013001295A1 (fr)
CO (1) CO6761350A2 (fr)
CR (1) CR20130213A (fr)
CU (1) CU20130069A7 (fr)
DO (1) DOP2013000105A (fr)
EA (1) EA024406B1 (fr)
EC (1) ECSP13012618A (fr)
GT (1) GT201300121A (fr)
IL (1) IL226066A0 (fr)
MA (1) MA34655B1 (fr)
MX (1) MX2013005305A (fr)
MY (1) MY164730A (fr)
NZ (1) NZ610018A (fr)
PE (1) PE20140411A1 (fr)
PH (1) PH12013500938A1 (fr)
SG (1) SG190100A1 (fr)
TW (1) TW201305170A (fr)
UA (1) UA113280C2 (fr)
UY (1) UY33719A (fr)
WO (1) WO2012062748A1 (fr)
ZA (1) ZA201304244B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9730943B2 (en) * 2010-11-11 2017-08-15 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
CN103370320B (zh) * 2010-11-11 2016-04-27 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
EP2508525A1 (fr) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CN103214489B (zh) * 2013-02-25 2016-10-26 中国人民解放军第二军医大学 一类具有抗肿瘤活性的多靶点激酶抑制剂及其制备方法
UA119537C2 (uk) * 2013-04-08 2019-07-10 Байєр Фарма Акцієнгезелльшафт ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
WO2015082376A2 (fr) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Utilisation d'inhibiteurs de pi3k
US10124007B2 (en) 2013-12-03 2018-11-13 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
JP6499657B2 (ja) 2013-12-03 2019-04-10 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ阻害剤の組み合わせ
WO2016071380A1 (fr) * 2014-11-07 2016-05-12 Bayer Pharma Aktiengesellschaft Synthèse d'inhibiteur de pi3k et ses sels
WO2016071382A1 (fr) * 2014-11-07 2016-05-12 Bayer Pharma Aktiengesellschaft Synthèse d'un inhibiteur de pi3k et de ses sels
WO2016087488A1 (fr) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Régime d'administration de dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués par un amino-alcool
WO2016087490A1 (fr) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de la voie pi3k
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
CA3037626A1 (fr) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de la pi3k
CN110381997A (zh) 2016-12-12 2019-10-25 茂体外尔公司 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物
WO2018215282A1 (fr) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de bub1 et de pi3k
EP3645005A1 (fr) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combinaison d'un inhibiteur de pi3k et d'un antagoniste du récepteur des androgènes
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
CN108383849B (zh) * 2018-04-26 2020-11-06 浙江大学 咪唑并喹唑啉衍生物及其在抗肿瘤抗炎中的应用
MX2021010669A (es) * 2019-03-07 2021-09-28 BioNTech SE Proceso para la preparacion de una imidazoquinolina sustituida.
US20230029385A1 (en) * 2019-10-15 2023-01-26 Bayer Aktiengesellschaft 2-methyl-aza-quinazolines
WO2021113644A1 (fr) 2019-12-05 2021-06-10 Multivir Inc. Combinaisons comprenant un activateur de lymphocytes t cd8+, un inhibiteur de point de contrôle immunitaire et une radiothérapie en vue d'obtenir des effets ciblés et abscopal pour le traitement du cancer
WO2021260443A1 (fr) 2020-06-24 2021-12-30 Bayer Aktiengesellschaft Associations de 2,3-dihydroimidazo[1,2-c]quinazolines
CN115572256B (zh) * 2021-06-21 2025-01-24 武汉睿健医药科技有限公司 Oct4高选择性活化剂
CN113512040B (zh) * 2021-08-25 2023-10-13 河南牧业经济学院 一种血根碱仿生化合物及其制备方法
TW202404968A (zh) * 2022-04-20 2024-02-01 美商思諾維新醫藥公司 ＰＩ３Ｋα抑制劑
US20250346603A1 (en) * 2022-05-26 2025-11-13 Pikavation Therapeutics, Inc. Tricyclic compounds as pi3kalpha inhibitors
AU2024361550A1 (en) * 2023-10-17 2026-04-09 Pikavation Therapeutics, Inc. 5-oxo-4,5-dihydroimidazo[1,5-a]quinazoline compounds as pi3k[alpha] inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB9400680D0 (en) 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
US5792766A (en) 1996-03-13 1998-08-11 Neurogen Corporation Imidazo 1,5-c! quinazolines; a new class of GABA brain receptor ligands
AU2003293310B2 (en) * 2002-09-30 2010-04-01 Bayer Intellectual Property Gmbh Fused azole-pyrimidine derivatives
MXPA06003113A (es) 2003-09-19 2006-06-20 Astrazeneca Ab Derivados de quinazolina.
EP1673087B1 (fr) * 2003-10-03 2015-05-13 3M Innovative Properties Company Imidazoquinolines a substitution alcoxy
US7842701B2 (en) * 2004-02-19 2010-11-30 Takeda Pharmaceutical Company Limited Pyrazoloquinolone derivative and use thereof
AU2006346931B2 (en) 2006-08-03 2012-07-19 Rottapharm Biotech S.R.L. 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
GB2454549B (en) * 2007-09-25 2009-09-23 Medical & Pharm Ind Tech & Dev Uses of 2-[piperidinyl]methyl-2,3-dihydroimidazo[1,2-c]quinazolin-5(6H)-one for providing an anti-allergic effect and histamine H1 receptor antagonism effect
BRPI0822462A2 (pt) 2008-06-20 2015-10-13 Rottapharm Spa derivados de 6-1h-imidazo-quinazolina e de quinolinas, novos inibidores de mao e ligantes a receptor de imidazolina.
AU2009264431B2 (en) 2008-06-26 2013-11-07 Nerviano Medical Sciences S.R.L. Pyrazolo-quinazolines
EP2168583A1 (fr) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Utilisation de 2,3-dihydroimidazo[1,2-c]quinazolines substituées pour le traitement du myélome
PE20130191A1 (es) 2010-04-16 2013-02-21 Bayer Ip Gmbh Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida
CN103370320B (zh) * 2010-11-11 2016-04-27 拜耳知识产权有限责任公司 芳基氨基醇取代的2,3-二氢咪唑并[1,2-c]喹啉
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
US9730943B2 (en) * 2010-11-11 2017-08-15 Bayer Intellectual Property Gmbh Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines

Also Published As

Publication number Publication date
MX2013005305A (es) 2013-06-13
CN102906094B (zh) 2016-06-22
AU2011328192B2 (en) 2016-09-01
US8895549B2 (en) 2014-11-25
BR112013011634A2 (pt) 2018-12-11
KR20140003436A (ko) 2014-01-09
AU2011328192A1 (en) 2013-05-02
CU20130069A7 (es) 2013-09-27
AP2013006921A0 (en) 2013-06-30
GT201300121A (es) 2014-12-22
DOP2013000105A (es) 2013-09-30
CR20130213A (es) 2013-07-01
PH12013500938A1 (en) 2013-07-08
EA024406B1 (ru) 2016-09-30
JP6196156B2 (ja) 2017-09-13
CN102906094A (zh) 2013-01-30
UY33719A (es) 2012-06-29
TW201305170A (zh) 2013-02-01
ECSP13012618A (es) 2013-07-31
UA113280C2 (xx) 2017-01-10
JP2013542238A (ja) 2013-11-21
US9902727B2 (en) 2018-02-27
AR083842A1 (es) 2013-03-27
CA2817317A1 (fr) 2012-05-18
IL226066A0 (en) 2013-06-27
US20130317004A1 (en) 2013-11-28
WO2012062748A1 (fr) 2012-05-18
EP2638045A1 (fr) 2013-09-18
AP3337A (en) 2015-07-31
EP2638045B1 (fr) 2022-08-31
SG190100A1 (en) 2013-07-31
ZA201304244B (en) 2014-12-23
CA2817317C (fr) 2020-07-14
CL2013001295A1 (es) 2013-10-04
NZ610018A (en) 2016-03-31
MY164730A (en) 2018-01-30
HK1180685A1 (zh) 2013-10-25
PE20140411A1 (es) 2014-04-13
CO6761350A2 (es) 2013-09-30
US20150080374A1 (en) 2015-03-19
EA201300556A1 (ru) 2013-10-30

Similar Documents

Publication Publication Date Title
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA47447A (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA30406B1 (fr) Nouveaux composes
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA31867B1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
PH12013500938A1 (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA29568B1 (fr) Composes d'azaindazole et methodes d'utilisation desdits composes
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
MA30765B1 (fr) Derives innovants du thiophene
MY143795A (en) Tetrahydropyridoindole derivatives
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA30514B1 (fr) Nouveaux composes.
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MA34158B1 (fr) Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA29723B1 (fr) Composes